http://www.neurology.org/cgi/content/abstract/57/2/342
Brief Communications
Neurology 2001;57:342-344
F. Nicoletti, MD, R. Di Marco, MD,
PhD, K. Mangano, F. Patti, MD, E. Reggio, MD, A. Nicoletti, MD, K. Bendtzen,
MD, Prof; and A. Reggio, MD, Prof
From the Institute of Microbiology
(Dr. F. Nicoletti), University of Milan Bicocca; Department of Microbiological
and Gynecologic Sciences (Drs. Di Marco and Mangano) and Institute of Neurology
(Drs. Patti, E. Reggio, A. Nicoletti, and A. Reggio), University of Catania,
Italy; and Institute for Inflammation Research (Dr. Bendtzen), Rigshospitalet
University Hospital, Copenhagen, Denmark.
Address correspondence and reprint
requests to Dr. Ferdinando Nicoletti, Via Luigi Sturzo n. 3, 95021, Cannizzaro,
Catania, Italy.
Serum but not CSF concentrations
of the interferon--inducing cytokine interleukin (IL)-18 were significantly
augmented in patients with MS as compared to both healthy controls and
patients with other neurologic diseases.
Patients with MS with secondary chronic
progressive disease had significantly higher serum levels than those with
relapsing remitting MS. In the latter group, IL-18 levels were higher in
patients with acute exacerbation as compared to those with stable disease.
© 2001 American Academy of
Neurology